BLDM, While I must admit I share your sentiment
Post# of 72447
Posted On: 07/14/2016 11:51:32 AM
BLDM,
While I must admit I share your sentiment about finding out of the B SPA delay through an SA interview article, I do want to point out that the B-OM trial is not purely to prove the anti-inflammatory properties of B. As stated by CTIX on the website: "Brilacidin has shown antibacterial, anti-biofilm and anti-inflammatory properties in various pre-clinical studies. We believe that the combination of these attributes contribute to the efficacy that brilacidin has shown in animal models of oral mucositis. - See more at: http://cellceutix.com/brilacidin-om/#sthash.o...puf."
So that's why it appears to many of us that Dr. Bertolino's course correction for the company trajectory on B seems to be very savvy. They have excellent data for B ABSSSI phase 2 showing the antibiotic aspect. B-UP will give much better anti-inflammatory data, and B-OM will be the trifecta including the anti-biofilm property. Therefore, if B-OM can be the fastest path to market, while demonstrating all three of the critical properties, then it will be a lock to demonstrate the value of the entire platform and also much easier to gain the approvals of the alternative indications. This means our friends at JNJ, or whoever the BP working on biofilm usage may be, will actually get to the usage of the drug faster. Plus our shareholder returns come in much sooner than waiting out the ABSSSI platform by itself.
While I must admit I share your sentiment about finding out of the B SPA delay through an SA interview article, I do want to point out that the B-OM trial is not purely to prove the anti-inflammatory properties of B. As stated by CTIX on the website: "Brilacidin has shown antibacterial, anti-biofilm and anti-inflammatory properties in various pre-clinical studies. We believe that the combination of these attributes contribute to the efficacy that brilacidin has shown in animal models of oral mucositis. - See more at: http://cellceutix.com/brilacidin-om/#sthash.o...puf."
So that's why it appears to many of us that Dr. Bertolino's course correction for the company trajectory on B seems to be very savvy. They have excellent data for B ABSSSI phase 2 showing the antibiotic aspect. B-UP will give much better anti-inflammatory data, and B-OM will be the trifecta including the anti-biofilm property. Therefore, if B-OM can be the fastest path to market, while demonstrating all three of the critical properties, then it will be a lock to demonstrate the value of the entire platform and also much easier to gain the approvals of the alternative indications. This means our friends at JNJ, or whoever the BP working on biofilm usage may be, will actually get to the usage of the drug faster. Plus our shareholder returns come in much sooner than waiting out the ABSSSI platform by itself.
(3)
(0)